Tukysa (tucatinib) is a prescription drug used to treat a kind of breast cancer known as HER2-positive metastatic breast cancer. It is commonly used in conjunction with other drugs such as trastuzumab (Herceptin) and capecitabine (a chemotherapy treatment).

HER2-positive metastatic breast cancer

HER2-positive metastatic breast cancer, also known as HER2-positive advanced or stage IV breast cancer, is a subtype of breast cancer defined by an overexpression of a particular protein on the surface of cancer cells called human epidermal growth factor receptor 2 (HER2). Overexpression of the HER2 protein causes uncontrolled cell proliferation and division, increasing the cancer’s aggressiveness.

Here are some key points about HER2-positive metastatic breast cancer:

Breast cancer cells are often classified into subtypes based on the presence or lack of certain receptors on their surface. Breast cancer cells that are HER2-positive have an overabundance of HER2 receptors.

The term “metastatic breast cancer” refers to cancer that has progressed from the breast to other regions of the body, such as the bones, liver, lungs, or brain. This stage is considered advanced and is frequently more difficult to cure.

Aggressive Nature: When compared to HER2-negative breast cancers, HER2-positive breast cancers are more aggressive and have a greater chance of recurrence.

Targeted medicines: Following the discovery of HER2 overexpression, targeted medicines particularly designed to suppress HER2 signaling were developed. Targeted treatments used in the treatment of HER2-positive metastatic breast cancer include trastuzumab (Herceptin), pertuzumab (Perjeta), and ado-trastuzumab emtansine (Kadcyla).

Combination medicines: Depending on the particular patient’s condition and the degree of the disease, HER2-positive breast cancer is frequently treated with a combination of medicines, which may include targeted therapies, chemotherapy, hormone therapy, and/or radiation therapy.

Prognosis: The prognosis for HER2-positive metastatic breast cancer varies based on various factors, including the stage of diagnosis, response to treatment, and general health. Many individuals with this subtype of breast cancer now have a better prognosis thanks to advances in targeted therapy.

Patients with HER2-positive metastatic breast cancer usually need continual monitoring and therapy modifications as the illness progresses.

Individuals diagnosed with HER2-positive metastatic breast cancer should collaborate closely with their healthcare team to build a specific treatment plan and remain up-to-date on the newest advances in breast cancer research and therapy. Support from healthcare experts, family, and support groups can also be beneficial in coping with the physical and mental issues that come with this diagnosis.

touched pleased lovely woman

Benefits of Tukysa:

Tukysa key advantage is its potential to delay the course of HER2-positive metastatic breast cancer. It works by targeting and blocking the overexpressed HER2 protein in this form of cancer. Tukysa inhibits the function of HER2 and so helps to restrict the development and spread of cancer cells.

Side Effects:

Tukysa, like all drugs, may have negative effects. Tukysa’s most prevalent side effects include:

Nausea and exhaustion
Hand-foot syndrome (redness, swelling, and discomfort on the palms of the hands and/or the soles of the feet) is a condition in which the palms and soles of the feet become inflamed.
Increased liver enzymes

It is essential to note that these negative effects will not be experienced by everyone, and some people may suffer different or more severe side effects. Your healthcare practitioner will regularly monitor you during treatment and can advise you on how to manage adverse effects.


Tukysa prices might vary greatly based on your area, the dosage recommended, your insurance coverage, and any applicable patient assistance programs. Tukysa was around $18,500 per month in the United States, although this pricing may have altered.

You should speak with your healthcare practitioner and contact your insurance company or the manufacturer’s website for the most recent price and assistance options to obtain the most accurate and up-to-date information on the cost of Tukysa and any potential financial help programs.

Please keep in mind that medicine pricing and availability vary by location, so it’s critical to discuss your individual circumstances with your healthcare team to fully grasp the cost and choices accessible to you.

Who created Tukysa?

Seattle Genetics, Inc., a biotechnology business located in the United States, produced Tukysa (tucatinib). Seattle Genetics is a company that focuses on developing targeted cancer medicines and antibody-drug conjugates. Tukysa was developed as a therapy for HER2-positive metastatic breast cancer and got FDA clearance in April 2020 for this use.

Tukysa was developed through comprehensive clinical trials and research to establish its safety and effectiveness in the treatment of HER2-positive breast cancer. It has become a significant addition to the therapy choices for those who have this form of breast cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *